Advanced Prostate Cancer VL

ENZADA, A Phase II Trial of Enzalutamide, Docetaxel, and Androgen Deprivation in Patients with Metastatic Hormone Sensitive Prostate Cancer - Earle Burgess

Details
(Length of Discussion: 12 min) Alicia Morgans and Earle Burgess discuss the details of the investigator-initiated trial called ENZADA. They discuss the “why” behind the design of this Phase II trial. Their desire is to understand whether or not triplicate therapy with ADT, plus docetaxel, plus a next gen endocrine agent will further improve outcome over either agent alone in this patient populatio...

TRIUMPH Study: Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations - Mark Markowski

Details
(Length of Discussion: 12 min) Alicia Morgans discusses with Mark Markowski details of the TRIUMPH trial, a single-arm, phase II trial, open-label using a PARP inhibitor rucaparib, in the absence of androgen deprivation therapy in men with metastatic hormone-naive prostate cancer. Biographies: Mark Christopher Markowski, MD., Ph.D., Assistant Professor of Oncology, John Hopkins Medicine Alicia Mor...

Assessment of Simplified Methods for Quantification of 18F FDHT Uptake Scans in Patients with Metastasized Castrate-Resistant Prostate Cancer - Gem Kramer

Details
(Length of Presentation: 8 min) This presentation represents a study performed to assess if [18F]FDHT PET/CT could be a valuable imaging biomarker in patients with prostate cancer. Biographies: Gem Kramer, Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands Read the Full Video Transcript

The Role of the PARP Inhibitor in Treating Prostate Cancer: Interview with Joaquin Mateo

Details
(Length of Conversation: 8 min) Alicia Morgans and Joaquin Mateo discuss the PARP inhibitor space in treating advanced prostate cancer and how this data can lead to a clinical practice of selecting the right patients who will benefit the most while trying to understand the optimal timing of adding these therapies. Biographies: Joaquin Mateo, MD, Ph.D., The Institute of Cancer Research & The Royal...

Current State of Liquid Biopsies in Prostate Cancer - Gert Attard

Details
(Length of Interview: 13 min) Charles Ryan and Gert Attard discuss what is currently being done with regards to serum analysis, plasma analysis, liquid biopsies, circulating tumor cells, in the field of prostate cancer. Biographies: Professor Gerhardt Attard MD Ph.D. FRCP Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He...

PSMA Imaging and Theranostics: Future Impact to Patient Management– Robert Flavell

Details
(Length of presentation: 30 min) In an interview with Phil Koo, Robert Flavell describes diagnostic and therapeutic applications of new agents in the management of patients with prostate cancer with initial high-risk diagnosis and biochemical recurrence. Biographies: Robert R. Flavell, MD, Ph.D., Assistant Professor in Residence Department of Radiology, Section of Nuclear Medicine, University of C...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe